Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 18;224(12):2094–2104. doi: 10.1093/infdis/jiab266

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

PMC Copyright notice

Figure 4. — Metronidazole treatment is associated with changes in concentrations of immune mediators in cervicovaginal lavage (CVL) fluid. Concentration of CXCL9 in CVL at visit 1 in patients who subsequently did or did not respond to metronidazole treatment as defined by change in Shannon diversity index (A). The change (Δ) between visit 3 and visit 1 in CVL fluid concentrations of CXCL9 (B), CXCL10 (C), monocyte chemoattractant protein 1 (MCP-1; D), interleukin 1α (IL-1α; E), interleukin 1β (IL-1β; F), secretory leukocyte protease inhibitor (SLPI; G), and Escherichia coli inhibitory activity (H) comparing responders and nonresponders to metronidazole. Circles indicate Bronx and triangles Thika participants. Data are presented as mean plus standard error and asterisks indicate differences between responders and nonresponders (*P < .05, **P < .01, ***P < .001, ****P < .0001).